Advertisement

Anesthesia

Shares of Parsippany, N.J.-based Pacira Pharmaceuticals fell more than 12 percent Tuesday after the company reported that the FDA will take three more months to review Exparel, its extended release local anesthetic, according to a Sign on San Diego report.

The American Society of Anesthesiologists recently sent a letter to the FDA that discussed the extent of anesthesia drug shortages and offered recommendations on actions to reduce shortages, according to an ASA release.

Advertisement

Patients' expectations about analgesia and hyperalgesia can alter the efficacy of an opioid and lead to neurologic changes in the brain regions associated with evaluating pain intensity, according to a study reported in Pain Medicine News.

Advertisement